捷心隆(02115.HK)2021年經調整溢利3469.4萬元 同比增加29.9%
格隆匯3月31日丨捷心隆(02115.HK)公吿,截至2021年12月31日止年度全年業績,收益2.68億元,同比增加31.4%;經調整年內溢利3469.4萬元,同比增加29.9%;每股盈利2.47人民幣分;董事會建議派發截至2021年12月31日止年度末期股息每股0.67港仙。
集團預計,在疫苗接種率提高、經濟活動恢復以及全球各國政府推出特別貨幣及財政政策的支持下,亞洲經濟將繼續從COVID-19疫情中逐漸復甦。由於全球半導體短缺,本集團亦預計對半導體行業的投資將繼續增加,從而將推動對本集團無塵室產品的需求增長,原因為無塵室產品主要用於半導體廠房的無塵室。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.